Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F23%3A43921109" target="_blank" >RIV/00023752:_____/23:43921109 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10465025 RIV/00216208:11120/23:43925763

Výsledek na webu

<a href="https://journals.sagepub.com/doi/10.1177/02698811231179808" target="_blank" >https://journals.sagepub.com/doi/10.1177/02698811231179808</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/02698811231179808" target="_blank" >10.1177/02698811231179808</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?

Popis výsledku v původním jazyce

This article reviews the potential dual role of monoamine oxidase inhibitors (MAOIs) in the treatment of castration-resistant prostate cancer (CRPC) and the comorbid depression often seen in patients with CRPC. It examines the complex interactions between various cellular and neuroendocrine pathways, with particular emphasis on the intertwined roles of the hypothalamic-pituitary-adrenal (HPA) axis, androgenic hormones and their receptors in the development of both disorders. The text also emphasises the need for rigorous research to understand the complex relationship between MAOIs, CRPC and comorbid depression, and to investigate common biomarkers of the two conditions. Such findings may shed light on the potential therapeutic efficacy of MAOIs in the treatment of CRPC patients with comorbid depression.

Název v anglickém jazyce

Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?

Popis výsledku anglicky

This article reviews the potential dual role of monoamine oxidase inhibitors (MAOIs) in the treatment of castration-resistant prostate cancer (CRPC) and the comorbid depression often seen in patients with CRPC. It examines the complex interactions between various cellular and neuroendocrine pathways, with particular emphasis on the intertwined roles of the hypothalamic-pituitary-adrenal (HPA) axis, androgenic hormones and their receptors in the development of both disorders. The text also emphasises the need for rigorous research to understand the complex relationship between MAOIs, CRPC and comorbid depression, and to investigate common biomarkers of the two conditions. Such findings may shed light on the potential therapeutic efficacy of MAOIs in the treatment of CRPC patients with comorbid depression.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Psychopharmacology

ISSN

0269-8811

e-ISSN

1461-7285

Svazek periodika

37

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

1157-1160

Kód UT WoS článku

001009976100001

EID výsledku v databázi Scopus

2-s2.0-85162711116